Journal of Spectroscopy

Journal of Spectroscopy / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 6385165 | 8 pages | https://doi.org/10.1155/2019/6385165

The In Vivo Evaluation on Total Components from Extract of Aconitum Based on a New Analytic Method of Area under Absorbance-Wavelength Curve

Academic Editor: Jose S. Camara
Received20 Nov 2018
Revised28 Dec 2018
Accepted31 Dec 2018
Published03 Feb 2019

Abstract

Objective. To study oral pharmacokinetics of Aconitum extract in randomized Sprague-Dawley (SD) rats and observe the profile change in vivo between plasma concentration and time with an aim to disclose relevant delivery rule for total components from Aconitum extract and finally to evaluate the research of Aconitum sustained-release preparation. Methods. Randomized rats were administered orally with the single and multiple dose of Aconitum extract based on the clinical use of Aconitum injection. Blood samples were collected at predetermined interval time from an eye of rats. The concentration of total components in those samples was determined by a new analytic method of area under absorbance-wavelength curve, the data were analyzed by Drug and Statistics software, and then the pharmacokinetic parameters and compartment model were acquired and compared, respectively. Results. The pharmacokinetic parameters of single and multiple doses were similar, and both of them showed characteristics of the one-compartment model. Cav, DF, and AUCss were (2.075 ± 0.282) µg/ml, (2.405 ± 0.175), and (24.901 ± 0.422) µg/ml/h, respectively. However, the concentrations of total components in the fifth and sixth day were 0.32 and 0.44 µg/ml, which were lower than the value of Cav. Conclusion. The method of AUAWC is feasible for the pharmacokinetics study in vivo analysis on total components of Aconitum with good sensitivity, specificity, and repeatability. The results demonstrated that both absorption and elimination of total components from Aconitum extract in rats were rapid and pharmacokinetic behavior was consistent at the level of single and multiple doses, which confirms that Aconitum injection is available to transform the oral sustained-release preparation. This will bring a good instruction to the research of sustained-release preparation of traditional Chinese medicine (TCM), which still lacks of an evaluation method available for total components in vivo analysis.

1. Introduction

Aconitum is a famous traditional Chinese medicine that had been used extensively for centuries to treat pain resulted from arthritis and cancer and to strengthen the function of the heart [14]. The main bioactive components of Aconitum are Aconitum alkaloids with a narrow therapeutic index, and the activity is closely related to the structure which differs from the number, type, and position of the substituents [5]. Aconitum injection composed of raw Chuanwu and Caowu, a kind of traditional Chinese medicine injection, is used for treatment of serious pain in the terminal gastric and liver cancer and has significant analgesic effect without addiction [69]. Although it has such promising therapeutic effects, its potential neurotoxicity and cardiotoxicity are frequently observed in clinics [1013]. Aconitum injection is intramuscular in clinic with once or twice a day at 1∼2 ml every time according to the standard of the ministry of traditional Chinese medicines [14]. But, it has no good compliance for the patient and is only injected through the doctors in hospital. Therefore, it is reasonable for us to study oral Aconitum sustained-release preparation transformed from Aconitum injection due to its digestive tract treatment for serious pain from terminal gastric and liver cancer.

Pharmacokinetic study is very important for the development of sustained-release preparation. However, there is no good effectively analytic evaluation method to be used for the pharmacokinetics of total components of TCM. This is the major reason why the sustained-release preparations of TCM were variously reported in references but little marketed in clinic. Up to now, despite many related theories and hypotheses about pharmacokinetics of TCM have been reported to explain its pharmacokinetic behavior, the substantial progresses for total components have not been broken through in nature [1520]. There were many pharmacokinetic studies on Aconitum from references [2124] but still lacking of related information for total components of Aconitum. It was reported that Aconitum alkaloids were absorbed and metabolized in vivo rapidly, which were all based on some certain individual alkaloids with clear chemical structure such as aconitine, meaconitine, and hyaconitine by high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (HPLC-MS) [2527]. Nevertheless, the pharmacokinetic results of various individual components are difficult to reasonably clarify the total pharmacokinetic characteristics of TCM with complicated components. Hence, it is very necessary and urgent to establish an analytical method for pharmacokinetic study on total components of Aconitum.

Area under absorbance-wavelength curve (AUAWC) is an analytical method based on UV-visible (UV-Vis) spectrophotometry, which can be used for simultaneous determination of total components of TCM with a combination of mathematics and computer technology, and has being used successfully in our group. At present, despite the methods of HPLC and HPLC-MS are being used in more and more analytical fields, UV-Vis spectrophotometry is also applied for its special merits, especially analysis such as total flavonoids, total alkaloids, and total saponins dealing with total components. In vivo, though part of total components may possibly be metabolized as metabolites, the mother nuclear structure of metabolite does not always change and the absorption behavior in UV-Vis spectrophotometry is generally the same. Therefore, AUAWC can accurately illustrate the delivery tendency of total components concentration including metabolites in plasma with time change. It is proportional to the concentration of total components, which was proposed in 2012 and confirmed from the theory based on Lambert–Beer’s equation with EL constant [28, 29], as follows:

And, a series of trials related to AUAWC or its combination with HPLC were well performed and reported in the Journal of Spectroscopy in 2013 [30] and some good Chinese core journals, such as the content determination of total components in TCMs [3133] and the studies on in vitro release tests [3436] and in vivo pharmacokinetics [3739] of total components in compounds preparations of TCMs. As for the operation procedure, firstly, AUAWC can be calculated through Origin software. Then, the AUAWC of total components can be obtained after a subtraction of the AUAWC of the drug’s plasma sample to the AUAWC of the blank plasma sample, as shown in Figure 1. Thirdly, the concentration of total components is calculated through a linear equation in which the concentration of total components is the AUAWC at certain time. Subsequently, the profile between concentration and time can be drawn, and the pharmacokinetic parameters be obtained through DAS software, illustrating absorption, distribution, metabolism, and excretion for total components from TCM and their final delivery rule in vivo.

Nowadays, cancer increasingly affects people’s health and even becomes the leading cause of death with no presently good treatment criteria. Thus, in this study, the total components in rats from Aconitum extract, which was prepared according to the technique of Aconitum injection in the standard of the ministry of traditional Chinese medicines, were determined by the method of AUAWC. After an oral administration with the single and multiple doses of Aconitum extract, the pharmacokinetic parameters of total components will be analyzed to search for Aconitum's delivery rule in vivo, which will be helpful to bring a good research base for the Aconitum sustained-release preparation and a convenient oral administration for the cancer patients.

2. Materials and Methods

2.1. Apparatus

UV-Vis spectrum scan was measured on a TU-1901 spectrophotometer (Beijing Purkinje General Instrument Co., Ltd.) with the use of a 1.0 cm quartz cell, AR-2140 one millionth of electronic scale (Mettler-Tolido Instruments (Shanghai) Co., Ltd.); VXH-3 micro-vortex mixer (Shanghai Yuejin Medical Device Factory); and TDL-4 low-speed centrifuge (Shanghai Anting Science Instrument Factory).

2.2. Reagents

Aconitine was purchased from the National Institute for Control of Pharmaceutical and Biological Products (Beijing, China). The raw material of Chuanwu and Caowu was purchased from medicine market (Bozhou) and were authenticated by Professor Zehao Huang from Fujian University of Traditional Chinese Medicine. Extract of Aconitum was obtained from the Department of Pharmaceutics of Fujian University of Traditional Chinese Medicine. All other reagents were of analytical grade, and the water used in the experiment was double distilled.

2.3. Animals

Healthy Sprague-Dawley rats, weighing 0.20–0.22 kg, were purchased from SLAC Laboratory Animal Company (Shanghai, China, SCXK (HU) 2018-0005). All the rats were allowed to acclimate one week before experiment. All studies were in compliance with the Guidelines for the Care and Use of Laboratory Animals and approved by Institutional Animal Care and Use Committee in XBL-China.

2.4. Animal Administration and Sampling

SD rats were randomly divided into nine groups (eight rats each group) based on different interval times, one group of which was regarded as the blank group and the others were administered orally the extract of Aconitum. The rats were fasted overnight and administered Aconitum extract at a single dose of 0.6 mg/kg in the morning, which is equivalent to the one-time dose of Aconitum injection. Blood samples (about 2.5 ml) were collected from intraocular angular veins of each rat and placed into tubes with heparin sodium anticoagulant at predetermined interval times (0, 0.25, 0.5, 1, 2, 4, 6, 8, and 12 h). Then, blood samples were centrifuged immediately at 3800 r/min for 10 min, and the separated plasma samples were stored at −20°C until analysis. The rats were fed to acclimate for one week after taking blood and then administered the Aconitum extract again at a dose of 0.6 mg/kg for 7 d continuously. The blood samples were collected and processed as the same as single dose except the blood samples for stable drug concentration determination, which were taken in the morning of the fifth and sixth day before the rats were administered.

2.5. Method Validation
2.5.1. Preparation of Calibration Standards

The reference substance of aconitine was prepared in methanol before use with a total concentration of 213 μg/ml. Working solutions were prepared by diluting stock solution with methanol for further concentration series of 42.6, 17.04, 8.52, 4.26, 1.06, and 0.53 μg/ml.

2.5.2. Specificity

Specificity of the method was investigated by comparing chromatograms of processed blank plasma samples, the standard of aconitine, the blank plasma spiked with the aconitine, and plasma after oral administration of Aconitum extract. The AUAWC of plasma samples should be larger than that of blank plasma samples, so the interference of blank plasma can be eliminated by the difference value.

2.5.3. Linearity

In accordance with the UV-Vis spectrophotometry, methanol was used as the blank control. Each 0.2 ml blank plasma was precisely added above series of standard solutions to 4 ml, respectively, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength. An eight-point calibration curve was constructed by plotting the AUAWC against the concentration. The linearity of the calibration curve was evaluated by linear regression analysis.

2.5.4. Recovery

The extraction recovery and relative recovery of aconitine were determined by analyzing six replicates of QC samples at three concentration levels. The extraction recovery was calculated by comparing the AUAWC values (a) of extracted QC samples with those (a) in which the compounds were spiked directly to methanol. The relative recovery was evaluated by comparing the concentration calculated by substituting the AUAWC values (a) into the regression equation with the actual concentration.

2.5.5. Precision

The precision of the method was determined by analyzing QC samples at three concentration levels in six replicates. Intraday precision was assessed from replicate analyses () of QC samples at each concentration level on the same day. The precision was expressed as relative standard deviation (RSD) for each QC concentration. The precisions were required to be within ±15% RSD.

2.5.6. Difference

The difference of the blank plasma samples from randomized SD rats in a group was determined. The difference could be ignored if the RSD < ±15%.

2.5.7. Stability

The stability of drug plasma samples from rats was determined at different time periods, including their stability after three freeze-thaw cycles with a frozen temperature of −20°C and the stability of processed samples kept at room temperature for 8 h. Samples were considered to be stable if the values were within requirement of precision (<±15% RSD).

2.5.8. Sample Preparation and Test

A plasma sample of 0.2 ml was precisely diluted with methanol to 4 ml, vortexed for 2 min, and centrifuged at 3800 r/min for 10 min. Then, supernatant was used for a full UV-Vis spectrum scanning from 200 nm to 500 nm wavelength with methanol as a blank control.

2.5.9. Pharmacokinetics Study

The values of AUAWC from the blank plasma group and drug groups at different interval time periods were calculated using Origin software. When the mean AUAWC values of drug group were subtracted from that of the blank group, respectively, the increased AUAWC caused by total components was obtained correspondingly and then substituted into the linear equation to get the total components concentration in vivo. The pharmacokinetic models (one- versus two-compartment) were compared according to the AIC rule, with minimum AIC values being regarded as the best representation of the blood concentration-time dynamic data. A compartmental model of total components in rats was proposed by the DAS software. The pharmacokinetic parameters of total components in rats were expressed as mean ± RSD and were compared by the unpaired Student’s t-test using the Statistical Package for the Social Science (SPSS, version 18.0). The result was obtained according to the process as showed in Figure 2.

3. Results

3.1. Validation of the Method
3.1.1. Linearity

From Figure 3, there were no interference from endogenous or exogenous materials and linear in the range from 1.02 to 65.00 μg/ml. The typical calibration curve of aconitine in rat plasma was ΔAUAWC = 1.2355C + 3.2935 with a coefficient of correlation r = 0.9993.

3.1.2. Recovery

Six replicates at low, medium, high QC concentrations for aconitine were prepared for recovery, as shown in Table 1. The recoveries of aconitine were satisfactory and reproducible. The mean absolute recovery of aconitine was from 80.45 to 99.52% at three QC levels. The mean relative recovery was from 100.64 to 107.34% for aconitine at three QC levels.


AnalyteSpiked concentration (μg/ml)Extraction recoveryRelative recoveryPrecision
Mean (%)RSD (%)Mean (%)RSD (%)RSD (%)

Aconitine2.0399.525.44100.647.081.30
16.2581.183.01104.453.451.05
65.0080.451.26107.341.850.75

3.1.3. Precision

The intraprecision values were within ±15% RSD at all QC levels of aconitine in rats plasma as shown in Table 1. The data were considered to be acceptable for subsequent analysis of all the samples.

3.1.4. Difference

The UV-Vis scanning spectrum of blank plasma from randomized eight SD rats in single-dose and multidose trials was shown, respectively, in Figures 4 and 5. RSD of the AUAWC value was within ±15% as shown in Table 2, which indicated that there is little difference for the determination of the total components in different plasma from different randomized rats.


DoseValues of AUAWCMeanRSD (%)

Single dose46.0745.002.00
47.10
43.60
45.03
44.70
44.54
44.34
44.66

Multidose44.0444.682.20
45.32
44.26
46.84
43.63
46.04
45.19
44.98

3.1.5. Stability

The data in Table 3 obtained from determination of stability demonstrated that there was no significant degradation under the conditions tested. The plasma samples were stable at room temperature for 8 h, during three freeze-thaw cycles at −20°C.


Storage conditionsTimeAUAWC valueMeanRSD (%)

At room temperature for 8 h045.14545.7512.20
144.051
245.348
346.524
446.766
645.057
847.365

Three freeze-thaw cycles50.13652.2462.81
54.279
52.324

3.2. Pharmacokinetics Study
3.2.1. The Concentration-Time Curve

The validated method was applied to the study on pharmacokinetics of Aconitum extract in rats. The full wavelength scan for different plasma samples is illustrated in Figure 3. The mean AUAWC values of blank plasma samples and the AUAWC increased by total components are provided in Table 4. The profile of kinetic curve on concentration versus time in rats after administration is shown in Figures 6 and 7.


DoseTime (h)Mean AUAWC values of plasmaAUAWC values of drugConcentration (µg/ml)

Single dose0.0045.000.000.00
0.2545.980.980.00
0.5053.718.714.38
1.0057.6612.667.58
2.0058.4413.448.21
4.0057.7112.717.62
6.0054.349.344.89
8.0052.797.793.64
12.0049.134.130.68

Multiple dose−48.0047.183.690.32
−24.0048.553.840.44
0.0044.680.000.00
0.2548.814.130.68
0.5052.768.083.87
1.0051.817.133.11
2.0054.669.985.41
4.0052.738.053.85
6.0050.145.461.75
8.0049.925.241.58
12.0047.242.560.00

3.2.2. Pharmacokinetics

The main pharmacokinetic parameters of total components in rats after a single and multiple dose administration of Aconitum extract are shown in Table 5. Comparison of the pharmacokinetic parameters of two groups by the unpaired Student’s t-test revealed significant difference () among the important pharmacokinetic parameters, such as Cmax, AUC0∼48, and half-life (t1/2) in Table 6.


ParametersUnitSingle doseMultiple dose

t1/2h4.056 ± 0.0263.395 ± 0.049
Tmaxh2.000 ± 0.0542.000 ± 0.175
Cmaxµg/ml8.210 ± 0.3865.410 ± 0.404
AUC0∼12µg/ml/h24.555 ± 0.26424.901 ± 1.594
AUC0–∞µg/ml/h69.731 ± 0.22332.626 ± 1.601
CL/Fµg/ml/h0.278 ± 0.0920.682 ± 0.312
V1/Fmg/µg/ml1.627 ± 0.1233.338 ± 0.872
Cavµg/ml2.075 ± 0.282
AUCssµg/ml/h24.610 ± 0.422
DF2.405 ± 0.175


MethodP valueConclusion

In CmaxIndependent sample t-test0.424No significance
In AUC0∼12Independent sample t-test0.399No significance
t1/2Independent sample t-test0.300No significance
TmaxIndependent sample t-test0.106No significance

Following the above figures and tables, the concentration of total components in the fifth and sixth day was lower than the value of Cav, but close to that of 0.25 h after administration in the seventh day during the course of multiple oral dose of Aconitum extract. Meanwhile, the concentration-time curve in rats presented a single-peak phenomenon after a single or multiple oral dose of Aconitum extract. They indicated the concentration of total components decreased quickly after reaching the Cmax. In addition, Tmax of total components stayed the same for 2 h, but t1/2 was 3.395 h after a multiple dose, and there was a trend of decrease compared with single dose; however, no significant difference was seen. The results further demonstrated that the absorption and excretion of total components in rats were rather rapid, which were characterized by the one-compartment model in this study, and they were consistent with the results in the studies [22, 4042]. From Table 6, there was no significant difference () in those pharmacokinetic parameters between the single-dose group and multiple-dose group. The cumulative ratio of Cmax and AUC0∼t (the value of AUC0∼12 in seventh day divided by that of the first day) were 0.658 and 0.418, and there were no accumulation of total components in rats after continuous administration for 7 d and once a day.

3.3. Discussion

From the view of biopharmaceutics, the drug concentration in rat plasma will wave greatly if the rats get a fright with blooding repeatedly, so randomized rats were sampled only one time for a rat and eight rats were divided in a group to improve the accuracy of the data. Moreover, the concentration of total components in the fifth and sixth day was lower than the value of Cav, which demonstrated that the valley concentration of Aconitum extract is a little small, and suggested the dose of sustained-release preparation, which is transformed from Aconitum injection, can be larger than that of injection. UV-Vis scan spectrum can well illustrate absorbance characteristics of total components in TCM, which is better than the method of HPLC in this point.

4. Conclusion

The method of AUAWC used is feasible for the in vivo evaluation study on total components of Aconitum with a convenience, quickness, and specificity response. In this study, compared with single dose, there were no significant change of the pharmacokinetic behavior and no risk of drug accumulation after continuous administration of Aconitum extract, which is beneficial to the research on sustained-release preparation of Aconitum and other TCMs.

Data Availability

The data in the article are available. Here, we state that the data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by guidance projects from Fujian Provincial Department of Science and Technology (2017Y0052).

References

  1. R. Pullela, L. Young, B. Gallagher, S. P. Avis, and E. W. Randell, “A case of fatal aconitine poisoning by Monkshood ingestion,” Journal of Forensic Sciences, vol. 53, no. 2, pp. 491–494, 2010. View at: Publisher Site | Google Scholar
  2. T. Y. K. Chan, “Aconite poisoning,” Clinical Toxicology, vol. 47, no. 4, pp. 279–285, 2009. View at: Publisher Site | Google Scholar
  3. C.-J. Tai, M. El-Shazly, T.-Y. Wu et al., “Clinical aspects of Aconitum preparations,” Planta Medica, vol. 81, no. 12-13, pp. 1017–1028, 2015. View at: Publisher Site | Google Scholar
  4. J. Singhuber, M. Zhu, S. Prinz, and B. Kopp, “Aconitum in Traditional Chinese Medicine-A valuable drug or an unpredictable risk?” Journal of Ethnopharmacology, vol. 126, no. 1, pp. 18–30, 2009. View at: Publisher Site | Google Scholar
  5. L. M. Gao and X. M. Wei, “Overview of the pharmacological action and structure-activity relationship of diterpenoid alkaloids,” Journal of Northwest Normal University, vol. 35, no. 1, pp. 98–103, 1999. View at: Google Scholar
  6. W. W. Fu, Y. Xue, J. Liu et al., “Analgesic effect of Aconitum injection on mice with pain,” Chinese Journal of Gerontology, vol. 25, no. 17, pp. 4768–4770, 2015. View at: Google Scholar
  7. D. H. Chen, “Clinical observation of 68 cases of cancer pain treated with Aconitum injection,” Proceedings of National Academic Conference on Integrated Chinese and Western Medicine, vol. 1, p. 140, 2000. View at: Google Scholar
  8. Y. Huang, L.H. Pan, B. Huang et al., “Clinical study on the application of scopolamine and Aconitum injection in the treatment of refractory advanced cancer pain,” Cancer prevention and treatment, vol. 17, no. 3, pp. 150–152, 2004. View at: Google Scholar
  9. M. Y. Huang and C. S. Li, “Analgesic effect and pharmacokinetic effect of Aconitum injection on mice,” Chinese Journal of Pharmacy, vol. 35, no. 9, pp. 613–615, 2000. View at: Google Scholar
  10. T. Y. K. Chan, “Aconite poisoning following the percutaneous absorption of Aconitum alkaloids,” Forensic Science International, vol. 223, no. 1-3, pp. 25–27, 2012. View at: Publisher Site | Google Scholar
  11. J. Q. Li, “Clinical analysis of 56 cases of arrhythmia caused by aconitine poisoning,” Contemporary Medicine, vol. 22, no. 2, pp. 40-41, 2016. View at: Google Scholar
  12. F. Moritz, P. Compagnon, I. G. Kaliszczak, Y. Kaliszczak, V. Caliskan, and C. Girault, “Severe acute poisoning with homemade Aconitum napellus capsules: toxicokinetic and clinical data,” Clinical Toxicology, vol. 43, no. 7, pp. 873–876, 2009. View at: Publisher Site | Google Scholar
  13. H. Niitsu, Y. Fujita, S. Fujita et al., “Distribution of Aconitum alkaloids in autopsy cases of aconite poisoning,” Forensic Science International, vol. 227, no. 1–3, pp. 111–117, 2013. View at: Publisher Site | Google Scholar
  14. Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia, vol. 1, China Medical Science Press, Beijing, China, 2015.
  15. Q. Zheng, P.-F. Yue, B. Wu, P.-Y. Hu, Z.-F. Wu, and M. Yang, “Pharmacokinetics comparative study of a novel Chinese traditional herbal formula and its compatibility,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 221–225, 2011. View at: Publisher Site | Google Scholar
  16. W. Tao, X. Xu, X. Wang et al., “Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease,” Journal of Ethnopharmacology, vol. 145, no. 1, pp. 1–10, 2013. View at: Publisher Site | Google Scholar
  17. S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013. View at: Publisher Site | Google Scholar
  18. S. S. Dou, R. H. Liu, P. Jiang et al., “System biology and its application in compound recipe of traditional Chinese medicine study,” World Science and Technology, vol. 10, no. 2, pp. 116–121, 2008. View at: Publisher Site | Google Scholar
  19. H. P. Hao, C. N. Zheng, and G. J. Wang, “Thoughts and experimental exploration on pharmacokinetic study of herbal medicines with multiple-components and targets,” Acta Pharmaceutica Sinica, vol. 44, no. 3, pp. 270–275, 2009. View at: Google Scholar
  20. S. X. You, C. J. Mao, Y. Cao et al., “Serum pharmacology of Chinese compound recipe huanglian injection,” Lishizhen Medicine and Materia Medica Research, vol. 23, no. 8, pp. 1873–1875, 2012. View at: Google Scholar
  21. R. P. Xiao, X. P. Lai, Y. Zhao, L. W. Yu, Y. L. Zhu, and G. Li, “Pharmacokinetic study of 6 alkaloids of aconite in beagle dogs,” Chinese Herbal Medicine, vol. 37, no. 2, pp. 284–287, 2014. View at: Google Scholar
  22. H. Zhang, S. Sun, W. Zhang et al., “Biological activities and pharmacokinetics of aconitine, benzoylaconine, and aconine after oral administration in rats,” Drug Testing and Analysis, vol. 8, no. 8, pp. 839–846, 2015. View at: Publisher Site | Google Scholar
  23. L. Chen, J. Yang, A. K. Davey, Y.-X. Chen, J.-P. Wang, and X.-Q. Liu, “Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism,” Xenobiotica, vol. 39, no. 12, pp. 955–963, 2009. View at: Publisher Site | Google Scholar
  24. Z. H. Wang, J. Wen, and Y. He, “Research on pharmacokinetics of aconitine by LC-MS,” Instrumental Analysis, vol. 23, no. 9, pp. 51–53, 2004. View at: Google Scholar
  25. Y. Yuan, X. M. Wang, G. X. Pan et al., “Determination of 8 Alkaloids in Aconitum species of 16 Chinese traditional patent medicine by LC-MS/MS,” Lishizhen Medicine and Materia Medica Research, vol. 26, no. 12, pp. 2823–2825, 2015. View at: Google Scholar
  26. J.-H. Chen, C.-Y. Lee, B.-C. Liau, M.-R. Lee, T.-T. Jong, and S.-T. Chiang, “Determination of aconitine-type alkaloids as markers in fuzi (Aconitum carmichaeli) by LC/(+)ESI/MS3,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 4, pp. 1105–1111, 2008. View at: Publisher Site | Google Scholar
  27. R. Kaneko, S. Hattori, S. Furuta et al., “Sensitive analysis of aconitine, hypaconitine, mesaconitine and jesaconitine in human body fluids and Aconitum, tubers by LC/ESI-TOF-MS,” Journal of Mass Spectrometry, vol. 41, no. 6, pp. 810–814, 2010. View at: Publisher Site | Google Scholar
  28. X. D. Li, S. Y. Li, L. H. Zhang, X. J. Xiao, C. Hou, and Z. Z. Yang, “Absorbance wavelength area under curve and linear relationship of drug concentration and its application in Chinese traditional medicine pharmacokinetic,” Journal of Fujian University of Traditional Chinese Medicine, vol. 22, no. 6, pp. 26–31, 2012. View at: Google Scholar
  29. H. Q. Lai, Y. Hu, and X. D. Li, “Investigation of the dissolution degree of the whole component of chuanxiong and its internal and external correlation based on the method of area under the absorbance-wavelength curve,” Journal of pharmacy, vol. 50, no. 6, pp. 788–792, 2015. View at: Google Scholar
  30. L. H. Zhang, X. J. Xiao, Z. Yang, M. Jiang, and X. Li, “A new method of area under the absorbance-wavelength curve for rats total metabolomic pharmacokinetics from yangxue injection with multicomponents,” Journal of Spectroscopy, vol. 2013, Article ID 919023, 8 pages, 2013. View at: Publisher Site | Google Scholar
  31. L. Yang, Z. X. Fan, and X. D. Li, “Comparative study on the amount of alkaline substances in different Chinese compound with equal quantity of Fuzi,” Chinese Herbal Medicine, vol. 47, no. 24, pp. 4364–4369, 2016. View at: Google Scholar
  32. L. Yang, Z. X. Fan, and X. D. Li, “Determination of alkaline substances in Aconitum injection by method of area under the absorbance-wavelength curve,” Fujian Journal of Traditional Chinese Medicine, vol. 48, no. 1, pp. 43-44, 2017. View at: Google Scholar
  33. L. Yang, M. M. Yang, and X. D. Li, “Determination of the content of medicinal materials in Aconitum injection and its particles by absorbing-wave area method,” Pharmaceutical research, vol. 37, no. 2, pp. 78–83, 2018. View at: Google Scholar
  34. H. Q. Lai, Y. Hu, and X. D. Li, “Study on the dissolution degree of whole and individual components of chuanxiong components by a combination of area under the absorbance-wavelength curve with HPLC,” Chinese Medicine Clinical Study, vol. 7, no. 14, pp. 6–10, 2015. View at: Google Scholar
  35. Z. Z. Yang, M. L. Jiang, and X. D. Li, “Study on the release degree of multiple components in the sol-gel capsule of hyacinth by the method of area under the absorbance-wavelength curve,” World Science and Technology-Modernization of Traditional Chinese Medicine, vol. 17, no. 1, pp. 197–204, 2015. View at: Google Scholar
  36. L. Yang and X. D. Li, “Determination of extracorporeal release of wutou binary drug particles by method of area under the absorbance-wavelength curve,” Chinese Journal of Experimental Formulation, vol. 23, no. 15, pp. 15–19, 2017. View at: Google Scholar
  37. X. D. Li, L. H. Zhang, and X. J. Xiao, “Study on the pharmacokinetics of yangxue injection in beagle dogs by area under the absorbance-wavelength curve and HPLC,” Chinese Journal of Pharmacy, vol. 49, no. 16, pp. 1442–1447, 2014. View at: Google Scholar
  38. Y. Hu, H. Q. Lai, Z. X. Fan et al., “Pharmacokinetics in rats by two methods of capsule component of Oldenlandia diffusa,” Chinese Journal of Experimental Formulations, vol. 21, no. 16, pp. 42–46, 2015. View at: Google Scholar
  39. Z. X. Fan, H. Q. Lai, X. D. Li et al., “Effects of single and multiple administration of Tougu xiaotong capsules on pharmacokinetic behavior in rats,” Chinese Journal of Experimental Formulation, vol. 22, no. 15, pp. 92–95, 2016. View at: Google Scholar
  40. K. Wada, M. Nihira, H. Hayakawa, Y. Tomita, M. Hayashida, and Y. Ohno, “Effects of long-term administrations of aconitine on electrocardiogram and tissue concentrations of aconitine and its metabolites in mice,” Forensic Science International, vol. 148, no. 1, pp. 21–29, 2005. View at: Publisher Site | Google Scholar
  41. L. Tang, Y. Gong, C. Lv, L. Ye, L. Liu, and Z. Liu, “Pharmacokinetics of aconitine as the targeted marker of Fuzi (Aconitum carmichaeli) following single and multiple oral administrations of Fuzi extracts in rat by UPLC/MS/MS,” Journal of Ethnopharmacology, vol. 141, no. 2, pp. 736–741, 2012. View at: Publisher Site | Google Scholar
  42. Z. Sui, N. Li, Z. Liu, J. Yan, and Z. Liu, “Metabolite profile analysis of aconitine in rabbit stomach after oral administration by liquid chromatography/electrospray ionization/multiple-stage tandem mass spectrometry,” Xenobiotica, vol. 43, no. 7, pp. 628–635, 2012. View at: Publisher Site | Google Scholar

Copyright © 2019 Miaomiao Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

501 Views | 204 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.